アフターアワーズ： 3.66 0.02 +0.55%

AbCellera Biologics Inc (ABCL)

AbCellera Biologics Inc (ABCL) 最新ニュース

AbCellera Biologics Inc (ABCL)

AbCellera Biologics Inc (ABCL) 最新ニュース

AbCellera Stock: If You Build It, Will They Come? Fresh Impetus Required (NASDAQ:ABCL) - Seeking Alpha

AbCellera Stock: Cash Providing Shelter From Market Weakness (NASDAQ:ABCL) - Seeking Alpha

Q2 2024 Earnings Forecast for AbCellera Biologics Inc. Issued By Bloom Burton (NASDAQ:ABCL) - MarketBeat

Bloom Burton Weighs in on AbCellera Biologics Inc.'s Q2 2024 Earnings (NASDAQ:ABCL) - Defense World

AbCellera Biologics Inc. to Post FY2026 Earnings of ($0.67) Per Share, Bloom Burton Forecasts (NASDAQ:ABCL) - Defense World

AbCellera Biologics (ABCL) Stock Forecast and Price Target 2024 - MarketBeat

Leerink Partnrs Comments on AbCellera Biologics Inc.'s Q2 2024 Earnings (NASDAQ:ABCL) - Defense World

AbCellera Biologics Inc. (NASDAQ:ABCL) Expected to Earn FY2026 Earnings of ($0.67) Per Share - MarketBeat

Earnings Release: Here's Why Analysts Cut Their AbCellera Biologics Inc. (NASDAQ:ABCL) Price Target To US$12.71 - Yahoo Finance

AbCellera Biologics (NASDAQ:ABCL) Price Target Lowered to $7.00 at KeyCorp - Defense World

KeyBanc lowers AbCellera Biologics shares target amid growth transition - Investing.com South Africa

AbCellera Biologics (NASDAQ:ABCL) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat

AbCellera Biologics (NASDAQ:ABCL) PT Lowered to $7.00 - MarketBeat

KeyBanc lowers AbCellera Biologics shares target amid growth transition - Investing.com Canada

KeyBanc lowers AbCellera Biologics shares target amid growth transition - Investing.com

AbCellera Biologics Inc. (NASDAQ:ABCL) Q1 2024 Earnings Call Transcript - Yahoo Finance

AbCellera Biologics (ABCL) Q1 2024 Earnings Call Transcript

AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Lifestyle UK

AbCellera Biologics (ABCL) Q1 2024 Earnings Call Transcript - The Globe and Mail

AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance

AbCellera Biologics Inc (ABCL) Q1 2024 Earnings: Misses Revenue and Net Loss Estimates - Yahoo Finance

AbCellera Reports Q1 2024 Business Results - 07.05.2024 - wallstreet:online

AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance

AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Lags Revenue Estimates - Yahoo New Zealand News

Strong week for AbCellera Biologics (NASDAQ:ABCL) shareholders doesn't alleviate pain of one-year loss - Yahoo Movies Canada

AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Tops Revenue Estimates - Yahoo News Australia

AbCellera Biologics Inc. (NASDAQ:ABCL) Receives $15.86 Average PT from Analysts - Defense World

Venture report: Rounds for psychedelic play Reunion, cancer company Delphia - BioCentury

Insider Stock Buying Reaches US$1.61m On AbCellera Biologics - Yahoo Finance

Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies - Business Wire

AbCellera Biologics Inc. (NASDAQ:ABCL) Receives Average Recommendation of "Buy" from Analysts - MarketBeat

AbCellera partners with PE firms to develop antibody drugs, company creation - Seeking Alpha

Vancouver biotech company plans $701M expansion, with $300M coming from government - Grand Forks Gazette

Analysts Estimate AbCellera Biologics Inc. (ABCL) to Report a Decline in Earnings: What to Look Out for

AbCellera Biologics (ABCL) to Release Earnings on Tuesday - MarketBeat

Analysts Estimate AbCellera Biologics Inc. (ABCL) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance Australia

In the wake of AbCellera Biologics Inc.'s (NASDAQ:ABCL) latest US$91m market cap drop, institutional owners may be forced to take severe actions - Simply Wall St

AbCellera advances T-cell cancer therapy with new data - Investing.com Nigeria

AbCellera advances T-cell cancer therapy with new data - Investing.com Canada

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024 - Yahoo Finance

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024 - Yahoo Finance

Combining ADCs with protein degraders could widen the therapeutic windows of both - BioCentury

Bearish bets, torpedo stocks and short squeezes on the TSX - The Globe and Mail

AbCellera and Biogen link on neurological antibody therapy - Pharmaceutical Technology

Abcellera To Collaborate With Biogen To Discover Therapeutic Antibodies For Neurological Conditions - XM

Vancouver readies for its position as a global pharma capital as B.C.'s biotech boom takes off - The Globe and Mail

AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024 - Business Wire

AbCellera Biologics Insiders Added US$1.61m Of Stock To Their Holdings - Simply Wall St

AbCellera: Victim Of Its Own Success (NASDAQ:ABCL) - Seeking Alpha

ABCLに似た銘柄